selpercatinib
selpercatinib: sourced relationships with 1 company · 7 clinical trials tracked · 2 FDA decisions.
selpercatinib evidence translation
What we can confirm
2 FDA records · 7 tracked trials
What it means
What to watch
Prepared research question
How could selpercatinib → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| ELI LILLY & Co (LLY) Reported 2020-05-08 · Current development: unknownSource Carcinoma, Transitional Cell | Approved |
| ELI LILLY & Co (LLY) Reported 2020-05-08 · Current development: unknownSource Solid Tumor; Carcinoma, Non-Small-Cell Lung | Phase 4 |
Clinical Trial Registry Records (7)
A Phase 4, Single-Arm Study to Evaluate the Safety of Selpercatinib in Participants With RET-Altered Cancers in India
Primary endpoint: Number of Participants Treatment Emergent Adverse Event(s) (TEAEs)
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Primary endpoint: Event-Free Survival (EFS)
Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers
Primary endpoint: Objective response rate (ORR)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Primary endpoint: Response rate by blinded independent centralized review (BICR)
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Primary endpoint: Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Primary endpoint: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with selpercatinib?
selpercatinib has dated SEC/FDA relationship records for ELI LILLY & Co.
How many clinical trials involve selpercatinib?
BioSniper tracks 7 clinical trials involving selpercatinib.
What is selpercatinib's latest FDA decision?
The most recent tracked FDA decision for selpercatinib is Approval, dated April 10, 2024.